Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BMImmune
Coralville, Iowa, United Statesbmimmune.life ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BMImmune is a pre-clinical stage biotechnology company focused on developing novel cancer immunotherapies by targeting lipid metabolism pathways. Founded by immunologist Dr. Bing Li, the company leverages research on fatty acid-binding proteins (FABPs), specifically FABP4 (adipose FABP) and FABP5, which link obesity, chronic inflammation, and cancer progression. BMImmune's lead program is a novel humanized monoclonal antibody targeting extracellular A-FABP (FABP4) for the treatment of triple-negative breast cancer (TNBC). By neutralizing circulating FABPs, the company aims to disrupt the metabolic support system of tumors and reduce the risk of obesity-associated cancer progression.
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on BMImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMImmune.